Patent · US Active

Rapidly disintegrating solid oral dosage forms containing dasatinib

US11344500B2 · kind B2 · utility

0Cited by

10References

22Claims

0Family size

Assignee

XSPRAY PHARMA AB · SE

Inventors

Per Andersson · Uppsala, SE
Thomas MEIJER · Viken, SE
Victor Söderberg · Uppsala, SE

Key dates

Filing date	Dec 2, 2020
Grant date	May 31, 2022
Priority date	—
Expiry date	Dec 3, 2040

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K31/506
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The instant application relates to the field of pharmaceutical compositions comprising dasatinb. Furthermore, the instant application relates to a method of treating proliferative disorders in a patient in need thereof, comprising administering a therapeutically effective amount of said compositions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.